title: Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: stratification of a high-risk population.
abstract: OBJECTIVE
  This work was undertaken to define the intrinsic cardiac risk of the patient population referred for dobutamine stress perfusion imaging and to determine whether dobutamine technetium-99m ((99m)Tc)-sestamibi single-photon emission computed tomography (SPECT) imaging is capable of risk stratification in this population.
  
  
  BACKGROUND
  In animal models, dobutamine attenuates the myocardial uptake of (99m)Tc-sestamibi resulting in underestimation of coronary stenoses. Therefore, we hypothesized that the prognostic value of dobutamine stress (99m)Tc-sestamibi SPECT myocardial perfusion imaging might be impaired, owing to reduced detection of coronary stenoses.
  
  
  METHODS
  We reviewed the clinical outcome of 308 patients (166 women, 142 men) who underwent dobutamine stress SPECT (99m)Tc-sestamibi imaging at our institution from September 1992 through December 1996.
  
  
  RESULTS
  During an average follow-up of 1.9 +/- 1.1 years, there were 33 hard cardiac events (18 myocardial infarctions [MI] and 15 cardiac deaths) corresponding to an annual cardiac event rate of 5.8%/year, which is significantly higher than the event rate for patients referred for exercise SPECT imaging at our institution (2.2%/year). Event rates were higher after an abnormal dobutamine (99m)Tc-sestamibi SPECT study (10.0%/year) than after a normal study (2.3%/year) (p < 0.01), even after adjusting for clinical variables. In the subgroup (n = 29) with dobutamine-induced ST-segment depression and abnormal SPECT imaging, the prognosis was poor, with annual cardiac death and nonfatal MI rates of 7.9% and 13.2%, respectively.
  
  
  CONCLUSIONS
  Patients referred for dobutamine perfusion imaging are a high-risk population, and dobutamine stress (99m)Tc-sestamibi SPECT imaging is capable of risk stratification in these patients.
authors.affiliation: Cardiovascular Division, Department of Medicine, Charlottesville, Virginia 22908-0158, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Calnon
authors.forename: P D
authors.initials: PD
authors.lastname: McGrath
authors.forename: A L
authors.initials: AL
authors.lastname: Doss
authors.forename: F E
authors.initials: FE
authors.lastname: Harrell
authors.forename: D D
authors.initials: DD
authors.lastname: Watson
authors.forename: G A
authors.initials: GA
authors.lastname: Beller
mesh_terms: D000368:Aged; D000818:Animals; D015982:Bias; D002316:Cardiotonic Agents / Q000494:pharmacology; D003327:Coronary Disease / Q000000981:diagnostic imaging* / Q000401:mortality; D004195:Disease Models, Animal; D004280:Dobutamine / Q000494:pharmacology; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012017:Referral and Consultation; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods* / Q000592:standards
chemical_list: D002316:Cardiotonic Agents; D019275:Radiopharmaceuticals; D004280:Dobutamine; D017256:Technetium Tc 99m Sestamibi